A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
The activity of trametinib and pembrolizumab is modest in NSCLC with increased toxicity compared with programmed death ligand 1 blockade alone. The recommended phase 2 dose for the combination is 2 mg of oral trametinib (d 1-10) and 200 mg of intravenous pembrolizumab every 21 days, with lead-in trametinib. Adverse events were comparable with other MEKi and ICI combination studies. Though limited clinical activity was observed, lead-in MEKi may induce favorable immune cell alterations.
Authors
- Miguel López de Rodas (ORCID: https://orcid.org/0000-0002-6062-4064)
- Emanual Maverakis
- Kurt A. Schalper (ORCID: https://orcid.org/0000-0001-5692-4833)
- Laurel Beckett (ORCID: https://orcid.org/0000-0002-2418-9843)
- Arta M. Monjazeb (ORCID: https://orcid.org/0000-0001-5175-8004)
- Primo N. Lara (ORCID: https://orcid.org/0000-0001-9512-0002)
- Karen Kelly (ORCID: https://orcid.org/0000-0002-2235-6636)
- Jonathan Wesley Riess (ORCID: https://orcid.org/0000-0001-7370-7304)
- Michiko Shimoda (ORCID: https://orcid.org/0000-0002-6627-4624)
- Guillaume Luxardi (ORCID: https://orcid.org/0000-0003-3338-0583)
- Matthew S Lara
- David R. Gandara
Institutions
- Yale Cancer Center (US)
- UC Davis Comprehensive Cancer Center
- University of California, Davis (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100806
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of California, Davis
- Stand Up To Cancer
- National Cancer Institute
- Comprehensive Cancer Center, University of California, Davis